Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

In an open-label, randomized, noninferiority trial, dolutegravir-based antiretroviral therapy was compared with standard care in children and adolescents starting first- or second-line therapy for HIV type 1 infection. Dolutegravir-based ART was superior to standard-care ART.

Uložené v:
Podrobná bibliografia
Vydané v:The New England journal of medicine Ročník 385; číslo 27; s. 2531 - 2543
Hlavní autori: Turkova, Anna, White, Ellen, Mujuru, Hilda A, Kekitiinwa, Adeodata R, Kityo, Cissy M, Violari, Avy, Lugemwa, Abbas, Cressey, Tim R, Musoke, Philippa, Variava, Ebrahim, Cotton, Mark F, Archary, Moherndran, Puthanakit, Thanyawee, Behuhuma, Osee, Kobbe, Robin, Welch, Steven B, Bwakura-Dangarembizi, Mutsa, Amuge, Pauline, Kaudha, Elizabeth, Barlow-Mosha, Linda, Makumbi, Shafic, Ramsagar, Nastassja, Ngampiyaskul, Chaiwat, Musoro, Godfrey, Atwine, Lorna, Liberty, Afaaf, Musiime, Victor, Bbuye, Dickson, Ahimbisibwe, Grace M, Chalermpantmetagul, Suwalai, Ali, Shabinah, Sarfati, Tatiana, Wynne, Ben, Shakeshaft, Clare, Colbers, Angela, Klein, Nigel, Bernays, Sarah, Saïdi, Yacine, Coelho, Alexandra, Grossele, Tiziana, Compagnucci, Alexandra, Giaquinto, Carlo, Rojo, Pablo, Ford, Deborah, Gibb, Diana M
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Massachusetts Medical Society 30.12.2021
Predmet:
ISSN:0028-4793, 1533-4406, 1533-4406
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Buďte prvý, kto okomentuje tento záznam!
Najprv sa musíte prihlásiť.